(Medical Xpress)—Using cutting-edge time-lapse photography, University of Southern California (USC) researchers have discovered clues to the development of the head at the cellular level, which could point scientists to ...
Feb 11, 2013
0
0
Leonidas Hill recently made history at Mattel Children's Hospital UCLA, when the 5-year-old became the first pediatric patient in the western United States to undergo transoral robotic surgery (TORS)—a minimally invasive ...
Dec 24, 2012
0
0
Research released today helps reveal how human and primate brains process and interpret facial expressions, and the role of facial mimicry in everything from deciphering an unclear smile to establishing relationships of power ...
Oct 15, 2012
0
0
(Medical Xpress)—The cellular cause of birth defects like cleft palates, missing teeth and problems with fingers and toes has been a tricky puzzle for scientists.
Sep 11, 2012
0
0
(HealthDay) -- There is considerable variation in the neuropsychological, behavioral, and academic outcomes of individuals with cleft lip and palate, as the outcomes are affected by developmental level, sex, and cleft type, ...
Aug 17, 2012
0
0
US regulators were expected to decide Tuesday whether to approve the second new anti-obesity drug in 13 years, Qnexa, which studies have shown may help some people lose up to 10 percent of their body weight.
Jul 17, 2012
0
0
(Medical Xpress) -- New research by medics at Trinity College Dublin suggests that folic acid plays a vital role in preventing a major birth defect. This is in addition to the established protection against neural birth defect ...
Jul 5, 2012
1
0
Children born with cleft lip, cleft palate and other craniofacial disorders face numerous medical challenges beyond appearance.
May 22, 2012
0
0
Patients with wider cleft palates appear more likely to postoperatively develop velopharyngeal insufficiency, a condition characterized by hypernasal speech and nasal air escape when speaking, according to a study published ...
Apr 16, 2012
0
0
US regulators will decide in July whether to approve Qnexa, the first obesity drug in more than a decade, extending the initial deadline by three months, the California-based drug-maker VIVUS said.
Apr 10, 2012
0
0
